Abstract: Quinoxalinedione derivatives of formula (I) ##STR1## are described, and their use in pharmaceutical agents.

Abstract: The disclosure relates to quinoxaline derivatives of Formula I ##STR1## wherein R.sup.1, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined in the disclosure, as well as their production and use in medicinal agents.

Abstract: Pyrido?1,2,3-de!quinoxaline derivatives of formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 each mean hydrogen, --POXY, halogen or --COR,R.sup.4 means hydrogen or OH,R.sup.5, R.sup.6 and R.sup.7 are the same or different and mean hydrogen, halogen, nitro, NR.sup.12 R.sup.13, cyano, CF.sub.3, C.sub.1-6 alkyl, C.sub.1-4 alkoxy, orR.sup.5 and R.sup.6 or R.sup.6 and R.sup.7 represent a fused benzene ring, and means a single or double bond,are described as well as their production and use in pharmaceutical agents.

Abstract: Compounds of formula I are described ##STR1## in which R.sup.1, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 have the meanings mentioned in the application as well as their production and use in pharmaceutical agents.

Abstract: Compounds of formula I ##STR1## are described, in which substituents R.sup.1 -R.sup.4 have the meanings mentioned in the application as well as their production and use in pharmaceutical agents.

Abstract: Hetaryloxy-.beta.-carbolines of formula I ##STR1## in which R.sup.A means a triazine or benzocondensed hetaryl radical with 1-2 nitrogen atoms optionally substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 or a 5- or 6-membered hetaryl radical with 1-2 nitrogen atoms substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1are useful pharmaceutical agents.

Abstract: The use of NMDA receptor antagonists or their physiologically compatible salts for preventing the development of tolerance during the long-term treatment with benzodiazepine-receptor-binding active ingredients as well as the combination of new pharmaceutical agents with benzodiazepine-receptor-binding active ingredients is described.

Abstract: Compounds of formula I are described ##STR1## in which R.sup.3 represents a C.sub.6-12 -aryl or hetaryl radical, optionally substituted singly or multiply with C.sub.1-4 -alkyl, C.sub.3-7 -cycloalkyl, halogen, C.sub.1-4 -alkoxy-C.sub.1-2 -alkyl, phenyl or amino, the process for their production and their use in pharmaceutical agents.

Abstract: .beta.-carbolines of formula I are described ##STR1## in which R.sup.A is a C.sub.6-12 aryl hetaryl as defined herein, that can be substituted singly to multiply with halogen, C.sub.1-4 -alkoxy, C.sub.1-4 -alkyl or amino,X is --(CH.sub.2).sub.n -- or --C.tbd.C--,for use as pharmaceutical agents.

Abstract: The use of the non-NMDA receptor antagonists quisqualate or kainate antagonists or their physiologically compatible salts for treatment of withdrawal symptoms after drug abuse as well as the combination of the new pharmaceutical agents with NMDA antagonists are described.

Abstract: .beta.-carboline-3-hydroxyalkylcarboxylic acid ester derivatives of formula I ##STR1## in which R.sup.A, n, R.sup.4 and R.sup.3, have the meaning indicated in the claims, as well as their production and their use in pharmaceutical agents are described.

Abstract: Hetaryloxy-.beta.-carbolines of formula I ##STR1## in which R.sup.A means a benzocondensed hetaryl radical with 1-2 nitrogen atoms optionally substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 or a 5- or 6-membered hetaryl radical with 1-2 nitrogen atoms substituted with halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, trifluoromethyl or SO.sub.2 --R.sup.1 are useful pharmaceutical agents.

Abstract: 4-Isoxazolyl-imidazole derivatives of formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings indicated, as well as their production and use in pharmaceutical agents, are described.

Abstract: Compounds of formula I ##STR1## in which R.sup.A, B (which is CR.sup.4) and R.sup.3 and have the meaning indicated in the application, as well as their production and their use in pharmaceutical agents, are described.

Abstract: Imidazole derivatives of general Formula I ##STR1## wherein R.sup.1 means hydrogen, an optionally substituted C.sub.1-10 hydrocarbon or hetaryl residue, or a cyclic ether residue,R.sup.2 means hydrogen, halogen, an optionally substituted amino, nitro, azide, thiocyanate or cyano group, a linear or branched C.sub.1-10 -alkyl residue optionally substituted with halogen, or -OR.sup.1 wherein R.sup.1 has the above-mentioned meanings, andR.sup.1 and R.sup.2 jointly with the oxygen atom form a saturated or unsaturated 5- to 7-membered ring which can contain still another hetero atom,R.sup.3 means hydrogen, a linear or branched C.sub.1-6 -alkyl group, or a C.sub.1-6 -alkoxyalkyl group,R.sup.4 means -COOR.sup.5, -CONR.sup.6 R.sup.7, -CN, ##STR2## and their use as medicinal agents are disclosed.